Raymond James on Aardvark Therapeutics Inc (AARD): 'credible path' at lower dose possible

March 24, 2026 1:02 PM EDT Send to a Friend
Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $28.00 price target on Aardvark Therapeutics Inc (NASDAQ: AARD)The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login